Articles, App Notes, Case Studies, & White Papers

  1. Non-Hodgkin Lymphoma – Global Clinical Trial Landscape - Focus On Asia Pacific 9/12/2023

    Gain a better understanding of the global clinical trial landscape of Non-Hodgkin lymphoma (NHL) and its trends in the Asia Pacific.

  2. Analytics And Bioassays Can Safely Fast-Track mRNA-LNP Drug Development 2/23/2023

    One main mRNA technology challenge is the formulation of delivery systems like lipid nanoparticles (LNPs). Learn about evading impurities in lipids, the future of mRNA-based genomic medicines, and more.

  3. Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing 8/5/2025

    Learn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.

  4. CQA Assessment Of LNP-Encapsulated IVT mRNA 4/21/2025

    Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.

  5. Choosing The Best mRNA Manufacturing Strategy 12/12/2025

    Choosing the right mRNA manufacturing model can define your success. Learn how to weigh control, cost, and flexibility to build a strategy that supports innovation and long-term growth.

  6. FAQs – RNA Therapies – Global Clinical Trials Landscape (2024) 8/19/2024

    Whether you’re a researcher, clinician, or industry professional, our FAQs will equip you with essential knowledge on the advancements and challenges in RNA therapy development.

  7. Europe At A Crossroads: Biotech Investment, Regulation, And Partnership In Real Life 12/10/2025

    Position your biotech for Europe’s next phase by aligning strong science, smart clinical strategy, and the right global partners to navigate funding, regulation, and growth.

  8. How To Establish Effective, Scalable Drug Safety Ops Across Vendors 7/9/2024

    Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.

  9. Filtration Of Viscous Materials For Microbial QC 2/12/2021

    Membrane filtration is the preferred method for sterility testing. Viscous products, such as oils, creams and ointments can prove difficult to filter. As per USP <71> viscous oils may be diluted as necessary with a suitable sterile diluent such as isopropyl myristate shown not to have antimicrobial activity in the conditions of the test. Sterile isopropyl myristate (IPM), has been shown to have no anti-microbial activity in test conditions. This study investigates the effectiveness of IPM as a diluent by comparing filtration times with unfiltered oils.

  10. PUPSIT As Part Of A Contamination Control Strategy (CCS) 8/21/2024

    Learn about the changes introduced in the latest revision to EU GMP Annex 1, and gain insight into the components that should be part of a PUPSIT risk assessment.